<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613248</url>
  </required_header>
  <id_info>
    <org_study_id>1602-006</org_study_id>
    <nct_id>NCT01613248</nct_id>
  </id_info>
  <brief_title>A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)</brief_title>
  <official_title>A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effectiveness, safety and tolerability of a range
      of doses of MK-1602 versus placebo in the treatment of acute migraine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>PF was defined as a reduction in headache severity from Grade 2 or 3 at Baseline to Grade 0. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pain Relief (PR) at 2 Hours Post-Dose</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>PR was defined as a reduction of a moderate or severe migraine headache (Grade 2 or 3) at Baseline to a mild headache or no headache (Grade 1 or 0) 2 hours post-dose. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With One or More Adverse Events Within 48 Hours Post-Dose</measure>
    <time_frame>Up to 48 hours post-dose</time_frame>
    <description>An AE is any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a sponsor product, whether or not considered related to the use of the product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With One or More Adverse Events Within 14 Days Post-Dose</measure>
    <time_frame>Up to 14 days post-dose</time_frame>
    <description>An AE is any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a sponsor product, whether or not considered related to the use of the product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued From Study Due to Adverse Events</measure>
    <time_frame>Up to 5 weeks post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Absence of Phonophobia at 2 Hours Post-Dose</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>Phonophobia is sensitivity to loud sounds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participant Reporting Absence of Photophobia at 2 Hours Post-Dose</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>Photophobia is sensitivity to bright light.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Absence of Nausea at 2 Hours Post-Dose</measure>
    <time_frame>2 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Sustained Pain Freedom (SPF) 2-24 Hours Post-Dose</measure>
    <time_frame>2-24 hours post-dose</time_frame>
    <description>SPF was defined as PF at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a mild/moderate/severe headache during the 24 hour period after dosing with study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting SPF 2-48 Hours Post-Dose</measure>
    <time_frame>2-48 hours post-dose</time_frame>
    <description>SPF was defined as PF at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a mild/moderate/severe headache during the 48 hour period after dosing with study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Sustained Pain Relief (SPR) 2-24 Hours Post-Dose</measure>
    <time_frame>2-24 hours post-dose</time_frame>
    <description>SPR was defined as PR at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the 24 hour period after dosing with study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting SPR 2-48 Hours Post-Dose</measure>
    <time_frame>2-48 hours post-dose</time_frame>
    <description>SPR was defined as PR at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the 48 hour period after dosing with study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Total Migraine Freedom (TMF) at 2 Hours Post-Dose</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>TMF at 2 hours post dose was defined as PF with no photophobia, phonophobia, nausea, or vomiting at 2 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting TMF at 2-24 Hours Post-Dose</measure>
    <time_frame>2-24 hours post-dose</time_frame>
    <description>TMF at 2-24 hours post-dose was defined as SPF with no photophobia, phonophobia, nausea, or vomiting during the 2 to 24 hour period after dosing with study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting TMF at 2-48 Hours Post-Dose</measure>
    <time_frame>2-48 hours post-dose</time_frame>
    <description>TMF at 2-48 hours post-dose was defined as SPF with no photophobia, phonophobia, nausea, or vomiting during the 2 to 48 hour period after dosing with study medication.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">834</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>MK-1602 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-1602 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-1602 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-1602 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-1602 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-1602</intervention_name>
    <description>Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.</description>
    <arm_group_label>MK-1602 1 mg</arm_group_label>
    <arm_group_label>MK-1602 10 mg</arm_group_label>
    <arm_group_label>MK-1602 25 mg</arm_group_label>
    <arm_group_label>MK-1602 50 mg</arm_group_label>
    <arm_group_label>MK-1602 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-matching MK-1602</intervention_name>
    <description>Single administration of placebo-matching MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rescue medication</intervention_name>
    <description>If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,
Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs]), anti-emetics, triptans or other medication not explicitly excluded.</description>
    <arm_group_label>MK-1602 1 mg</arm_group_label>
    <arm_group_label>MK-1602 10 mg</arm_group_label>
    <arm_group_label>MK-1602 25 mg</arm_group_label>
    <arm_group_label>MK-1602 50 mg</arm_group_label>
    <arm_group_label>MK-1602 100 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 1 year history of migraine with or without aura as defined by International Headache
             Society (IHS) criteria 1.1 and/or 1.2

          -  Migraines typically last between 4 to 72 hours, if untreated

          -  ≥ 2 and ≤ 8 moderate or severe migraine attacks per month in each of

        the two months prior to screening

          -  Male, female who is not of reproductive potential, or female of

        reproductive potential with a screening serum β-human chorionic gonadotropin (β-hCG) level
        consistent with a not-pregnant state, and who agrees to use acceptable contraception

        Exclusion Criteria:

          -  Pregnant or breast-feeding, or is a female expecting to conceive within the projected
             duration of study participation

          -  Participant has difficulty distinguishing his/her migraine attacks from tension-type
             headaches

          -  History of predominantly mild migraine attacks or migraines that usually

        resolve spontaneously in less than two hours

          -  More than 15 headache-days per month or has taken medication for acute headache on
             more than 10 days per month in any of the three months prior to screening

          -  Basilar-type or hemiplegic migraine headache

          -  &gt; 50 years old at age of migraine onset

          -  Taking migraine prophylactic medication where the prescribed daily dose

        has changed during the 3 months prior to screening and will not be changed

        during the study

          -  Taking a proton pump inhibitor (PPI) or a histamine receptor 2 (H2) blocker on a daily
             or near daily basis (&gt; 3 days per week)

          -  Taking the following medications from 1 month prior to screening through study period:
             potent cytochrome P450 (CYP) 3A4 inhibitors (e.g., cyclosporine, itraconazole,
             ketoconazole, fluconazole, erythromycin, clarithromycin, nefazodone, telithromycin,
             cimetidine, quinine, diltiazem, verapamil, and human immunodeficiency virus [HIV]
             protease inhibitors), moderate or marked CYP3A4 inducers (e.g., rifampicin, rifabutin,
             barbiturates [e.g., phenobarbital and primidone], systemic glucocorticoids,
             nevirapine, efavirenz, pioglitazone, carbamazepine, phenytoin, and St. Johns wort), or
             drugs with narrow therapeutic margins and potential for drug interactions in the CYP2C
             family (e.g., warfarin)

          -  Participant is unable to refrain from consumption of grapefruit or grapefruit juice
             during study

          -  History of hypersensitivity to, or has experienced a serious adverse event

        in response to 3 or more classes of drugs (prescription and over-the-counter)

          -  Clinical or laboratory evidence of uncontrolled diabetes, human immunodeficiency virus
             (HIV) disease, or significant pulmonary, renal, hepatic, endocrine, or other systemic
             disease

          -  Other confounding pain syndromes, psychiatric conditions such as uncontrolled major
             depression, dementia or significant neurological disorders other than migraine.
             Patients who are currently being treated with non-prohibited medication for depression
             and symptoms are well controlled are eligible to participate

          -  Participant is at imminent risk of self-harm

          -  History of malignancy ≤ 5 years prior to study, except for adequately treated basal
             cell or squamous cell skin cancer, or in situ cervical cancer

          -  History of gastric or small intestinal surgery (including gastric bypass

        surgery or banding), or presence of a disease that causes malabsorption

          -  Participant has recent history (within the last year) of drug or alcohol abuse or
             dependence or is a user of recreational or illicit drugs

          -  Participant is legally or mentally incapacitated

          -  Donation of blood products or phlebotomy of &gt; 300 ml within 8

        weeks of study, or intent to donate blood products or receive

        blood products within 30 days of screening and throughout study

          -  Intent to donate eggs or sperm within the projected duration of the

        study

          -  Current participation in or participation within 30 days of screening

        in a study with an investigational compound or device

          -  Previous exposure to MK-0974 and/or MK-3207

          -  Use within the past 2 months of an opioid- or barbiturate-containing

        analgesic for migraine relief

          -  Inpatient or emergency department treatment of an acute migraine

        attack within the past 2 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <results_first_submitted>August 8, 2016</results_first_submitted>
  <results_first_submitted_qc>August 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2016</results_first_posted>
  <last_update_submitted>August 8, 2016</last_update_submitted>
  <last_update_submitted_qc>August 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
        <group group_id="P2">
          <title>MK-1602 1 mg</title>
          <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
        <group group_id="P3">
          <title>MK-1602 10 mg</title>
          <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
        <group group_id="P4">
          <title>MK-1602 25 mg</title>
          <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
        <group group_id="P5">
          <title>MK-1602 50 mg</title>
          <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
        <group group_id="P6">
          <title>MK-1602 100 mg</title>
          <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="138"/>
                <participants group_id="P3" count="139"/>
                <participants group_id="P4" count="139"/>
                <participants group_id="P5" count="139"/>
                <participants group_id="P6" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="106"/>
                <participants group_id="P4" count="101"/>
                <participants group_id="P5" count="104"/>
                <participants group_id="P6" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="38"/>
                <participants group_id="P5" count="35"/>
                <participants group_id="P6" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Qualifying Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Subjects as Treated Population included all randomized participants who received at least 1 dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
        <group group_id="B2">
          <title>MK-1602 1 mg</title>
          <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
        <group group_id="B3">
          <title>MK-1602 10 mg</title>
          <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
        <group group_id="B4">
          <title>MK-1602 25 mg</title>
          <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
        <group group_id="B5">
          <title>MK-1602 50 mg</title>
          <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
        <group group_id="B6">
          <title>MK-1602 100 mg</title>
          <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="113"/>
            <count group_id="B2" value="107"/>
            <count group_id="B3" value="108"/>
            <count group_id="B4" value="104"/>
            <count group_id="B5" value="106"/>
            <count group_id="B6" value="102"/>
            <count group_id="B7" value="640"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.5" spread="11.7"/>
                    <measurement group_id="B2" value="39.6" spread="10.7"/>
                    <measurement group_id="B3" value="41.1" spread="10.9"/>
                    <measurement group_id="B4" value="41.4" spread="11.5"/>
                    <measurement group_id="B5" value="40.7" spread="12.3"/>
                    <measurement group_id="B6" value="41.9" spread="11.0"/>
                    <measurement group_id="B7" value="40.8" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 to 29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 to 39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 to 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="33"/>
                    <measurement group_id="B7" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 to 59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="91"/>
                    <measurement group_id="B5" value="92"/>
                    <measurement group_id="B6" value="90"/>
                    <measurement group_id="B7" value="559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose</title>
        <description>PF was defined as a reduction in headache severity from Grade 2 or 3 at Baseline to Grade 0. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.</description>
        <time_frame>2 hours post-dose</time_frame>
        <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O2">
            <title>MK-1602 1 mg</title>
            <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O3">
            <title>MK-1602 10 mg</title>
            <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O4">
            <title>MK-1602 25 mg</title>
            <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O5">
            <title>MK-1602 50 mg</title>
            <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O6">
            <title>MK-1602 100 mg</title>
            <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose</title>
          <description>PF was defined as a reduction in headache severity from Grade 2 or 3 at Baseline to Grade 0. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.</description>
          <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" lower_limit="4.4" upper_limit="15.8"/>
                    <measurement group_id="O2" value="5.6" lower_limit="2.1" upper_limit="11.8"/>
                    <measurement group_id="O3" value="14.8" lower_limit="8.7" upper_limit="22.9"/>
                    <measurement group_id="O4" value="21.4" lower_limit="13.9" upper_limit="30.5"/>
                    <measurement group_id="O5" value="21.0" lower_limit="13.6" upper_limit="30.0"/>
                    <measurement group_id="O6" value="25.5" lower_limit="17.4" upper_limit="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pain Relief (PR) at 2 Hours Post-Dose</title>
        <description>PR was defined as a reduction of a moderate or severe migraine headache (Grade 2 or 3) at Baseline to a mild headache or no headache (Grade 1 or 0) 2 hours post-dose. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.</description>
        <time_frame>2 hours post-dose</time_frame>
        <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O2">
            <title>MK-1602 1 mg</title>
            <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O3">
            <title>MK-1602 10 mg</title>
            <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O4">
            <title>MK-1602 25 mg</title>
            <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O5">
            <title>MK-1602 50 mg</title>
            <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O6">
            <title>MK-1602 100 mg</title>
            <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pain Relief (PR) at 2 Hours Post-Dose</title>
          <description>PR was defined as a reduction of a moderate or severe migraine headache (Grade 2 or 3) at Baseline to a mild headache or no headache (Grade 1 or 0) 2 hours post-dose. Headache severity was reported by the participant using a 4-point scale where: 0=no pain, 1=mild pain, 2=moderate pain and 3=severe pain.</description>
          <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" lower_limit="35.2" upper_limit="54.3"/>
                    <measurement group_id="O2" value="37.4" lower_limit="28.2" upper_limit="47.3"/>
                    <measurement group_id="O3" value="52.8" lower_limit="42.9" upper_limit="62.5"/>
                    <measurement group_id="O4" value="53.4" lower_limit="43.3" upper_limit="63.3"/>
                    <measurement group_id="O5" value="57.1" lower_limit="47.1" upper_limit="66.8"/>
                    <measurement group_id="O6" value="58.8" lower_limit="48.6" upper_limit="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Adverse Events Within 48 Hours Post-Dose</title>
        <description>An AE is any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a sponsor product, whether or not considered related to the use of the product.</description>
        <time_frame>Up to 48 hours post-dose</time_frame>
        <population>All Subjects as Treated (ASaT) population included all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O2">
            <title>MK-1602 1 mg</title>
            <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O3">
            <title>MK-1602 10 mg</title>
            <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O4">
            <title>MK-1602 25 mg</title>
            <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O5">
            <title>MK-1602 50 mg</title>
            <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O6">
            <title>MK-1602 100 mg</title>
            <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Adverse Events Within 48 Hours Post-Dose</title>
          <description>An AE is any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a sponsor product, whether or not considered related to the use of the product.</description>
          <population>All Subjects as Treated (ASaT) population included all randomized participants who received at least one dose of study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="107"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Adverse Events Within 14 Days Post-Dose</title>
        <description>An AE is any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a sponsor product, whether or not considered related to the use of the product.</description>
        <time_frame>Up to 14 days post-dose</time_frame>
        <population>ASaT population included all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O2">
            <title>MK-1602 1 mg</title>
            <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O3">
            <title>MK-1602 10 mg</title>
            <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O4">
            <title>MK-1602 25 mg</title>
            <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O5">
            <title>MK-1602 50 mg</title>
            <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O6">
            <title>MK-1602 100 mg</title>
            <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Adverse Events Within 14 Days Post-Dose</title>
          <description>An AE is any unfavorable and unintended change in the structure (signs), function (symptoms), or chemistry (laboratory data) of the body temporally associated with any use of a sponsor product, whether or not considered related to the use of the product.</description>
          <population>ASaT population included all randomized participants who received at least one dose of study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="107"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued From Study Due to Adverse Events</title>
        <time_frame>Up to 5 weeks post-dose</time_frame>
        <population>ASaT population included all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O2">
            <title>MK-1602 1 mg</title>
            <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O3">
            <title>MK-1602 10 mg</title>
            <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O4">
            <title>MK-1602 25 mg</title>
            <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O5">
            <title>MK-1602 50 mg</title>
            <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O6">
            <title>MK-1602 100 mg</title>
            <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued From Study Due to Adverse Events</title>
          <population>ASaT population included all randomized participants who received at least one dose of study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="104"/>
                <count group_id="O5" value="106"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Absence of Phonophobia at 2 Hours Post-Dose</title>
        <description>Phonophobia is sensitivity to loud sounds.</description>
        <time_frame>2 hours post-dose</time_frame>
        <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O2">
            <title>MK-1602 1 mg</title>
            <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O3">
            <title>MK-1602 10 mg</title>
            <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O4">
            <title>MK-1602 25 mg</title>
            <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O5">
            <title>MK-1602 50 mg</title>
            <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O6">
            <title>MK-1602 100 mg</title>
            <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Absence of Phonophobia at 2 Hours Post-Dose</title>
          <description>Phonophobia is sensitivity to loud sounds.</description>
          <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0" lower_limit="32.7" upper_limit="51.7"/>
                    <measurement group_id="O2" value="45.8" lower_limit="36.1" upper_limit="55.7"/>
                    <measurement group_id="O3" value="49.1" lower_limit="39.3" upper_limit="58.9"/>
                    <measurement group_id="O4" value="55.3" lower_limit="45.2" upper_limit="65.1"/>
                    <measurement group_id="O5" value="56.2" lower_limit="46.2" upper_limit="65.9"/>
                    <measurement group_id="O6" value="60.8" lower_limit="50.6" upper_limit="70.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participant Reporting Absence of Photophobia at 2 Hours Post-Dose</title>
        <description>Photophobia is sensitivity to bright light.</description>
        <time_frame>2 hours post-dose</time_frame>
        <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O2">
            <title>MK-1602 1 mg</title>
            <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O3">
            <title>MK-1602 10 mg</title>
            <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O4">
            <title>MK-1602 25 mg</title>
            <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O5">
            <title>MK-1602 50 mg</title>
            <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O6">
            <title>MK-1602 100 mg</title>
            <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participant Reporting Absence of Photophobia at 2 Hours Post-Dose</title>
          <description>Photophobia is sensitivity to bright light.</description>
          <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" lower_limit="22.0" upper_limit="39.8"/>
                    <measurement group_id="O2" value="37.4" lower_limit="28.2" upper_limit="47.3"/>
                    <measurement group_id="O3" value="43.5" lower_limit="34.0" upper_limit="53.4"/>
                    <measurement group_id="O4" value="39.8" lower_limit="30.3" upper_limit="49.9"/>
                    <measurement group_id="O5" value="47.6" lower_limit="37.8" upper_limit="57.6"/>
                    <measurement group_id="O6" value="54.9" lower_limit="44.7" upper_limit="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Absence of Nausea at 2 Hours Post-Dose</title>
        <time_frame>2 hours post-dose</time_frame>
        <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O2">
            <title>MK-1602 1 mg</title>
            <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O3">
            <title>MK-1602 10 mg</title>
            <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O4">
            <title>MK-1602 25 mg</title>
            <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O5">
            <title>MK-1602 50 mg</title>
            <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O6">
            <title>MK-1602 100 mg</title>
            <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Absence of Nausea at 2 Hours Post-Dose</title>
          <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" lower_limit="52.9" upper_limit="71.5"/>
                    <measurement group_id="O2" value="59.8" lower_limit="49.9" upper_limit="69.2"/>
                    <measurement group_id="O3" value="67.6" lower_limit="57.9" upper_limit="76.3"/>
                    <measurement group_id="O4" value="73.8" lower_limit="64.2" upper_limit="82.0"/>
                    <measurement group_id="O5" value="68.6" lower_limit="58.8" upper_limit="77.3"/>
                    <measurement group_id="O6" value="70.6" lower_limit="60.7" upper_limit="79.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Sustained Pain Freedom (SPF) 2-24 Hours Post-Dose</title>
        <description>SPF was defined as PF at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a mild/moderate/severe headache during the 24 hour period after dosing with study medication.</description>
        <time_frame>2-24 hours post-dose</time_frame>
        <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O2">
            <title>MK-1602 1 mg</title>
            <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O3">
            <title>MK-1602 10 mg</title>
            <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O4">
            <title>MK-1602 25 mg</title>
            <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O5">
            <title>MK-1602 50 mg</title>
            <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O6">
            <title>MK-1602 100 mg</title>
            <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Sustained Pain Freedom (SPF) 2-24 Hours Post-Dose</title>
          <description>SPF was defined as PF at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a mild/moderate/severe headache during the 24 hour period after dosing with study medication.</description>
          <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="106"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="2.5" upper_limit="12.3"/>
                    <measurement group_id="O2" value="4.7" lower_limit="1.5" upper_limit="10.6"/>
                    <measurement group_id="O3" value="9.3" lower_limit="4.5" upper_limit="16.4"/>
                    <measurement group_id="O4" value="14.6" lower_limit="8.4" upper_limit="22.9"/>
                    <measurement group_id="O5" value="15.1" lower_limit="8.9" upper_limit="23.4"/>
                    <measurement group_id="O6" value="21.6" lower_limit="14.0" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting SPF 2-48 Hours Post-Dose</title>
        <description>SPF was defined as PF at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a mild/moderate/severe headache during the 48 hour period after dosing with study medication.</description>
        <time_frame>2-48 hours post-dose</time_frame>
        <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O2">
            <title>MK-1602 1 mg</title>
            <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O3">
            <title>MK-1602 10 mg</title>
            <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O4">
            <title>MK-1602 25 mg</title>
            <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O5">
            <title>MK-1602 50 mg</title>
            <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O6">
            <title>MK-1602 100 mg</title>
            <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting SPF 2-48 Hours Post-Dose</title>
          <description>SPF was defined as PF at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a mild/moderate/severe headache during the 48 hour period after dosing with study medication.</description>
          <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="106"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="2.5" upper_limit="12.3"/>
                    <measurement group_id="O2" value="4.7" lower_limit="1.5" upper_limit="10.6"/>
                    <measurement group_id="O3" value="9.3" lower_limit="4.5" upper_limit="16.4"/>
                    <measurement group_id="O4" value="14.6" lower_limit="8.4" upper_limit="22.9"/>
                    <measurement group_id="O5" value="14.2" lower_limit="8.1" upper_limit="22.3"/>
                    <measurement group_id="O6" value="20.6" lower_limit="13.2" upper_limit="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Sustained Pain Relief (SPR) 2-24 Hours Post-Dose</title>
        <description>SPR was defined as PR at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the 24 hour period after dosing with study medication.</description>
        <time_frame>2-24 hours post-dose</time_frame>
        <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O2">
            <title>MK-1602 1 mg</title>
            <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O3">
            <title>MK-1602 10 mg</title>
            <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O4">
            <title>MK-1602 25 mg</title>
            <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O5">
            <title>MK-1602 50 mg</title>
            <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O6">
            <title>MK-1602 100 mg</title>
            <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Sustained Pain Relief (SPR) 2-24 Hours Post-Dose</title>
          <description>SPR was defined as PR at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the 24 hour period after dosing with study medication.</description>
          <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3" lower_limit="20.2" upper_limit="37.6"/>
                    <measurement group_id="O2" value="17.8" lower_limit="11.0" upper_limit="26.3"/>
                    <measurement group_id="O3" value="36.1" lower_limit="27.1" upper_limit="45.9"/>
                    <measurement group_id="O4" value="39.8" lower_limit="30.3" upper_limit="49.9"/>
                    <measurement group_id="O5" value="45.7" lower_limit="36.0" upper_limit="55.7"/>
                    <measurement group_id="O6" value="46.1" lower_limit="36.2" upper_limit="56.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting SPR 2-48 Hours Post-Dose</title>
        <description>SPR was defined as PR at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the 48 hour period after dosing with study medication.</description>
        <time_frame>2-48 hours post-dose</time_frame>
        <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O2">
            <title>MK-1602 1 mg</title>
            <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O3">
            <title>MK-1602 10 mg</title>
            <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O4">
            <title>MK-1602 25 mg</title>
            <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O5">
            <title>MK-1602 50 mg</title>
            <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O6">
            <title>MK-1602 100 mg</title>
            <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting SPR 2-48 Hours Post-Dose</title>
          <description>SPR was defined as PR at 2 hours post-dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the 48 hour period after dosing with study medication.</description>
          <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="17.3" upper_limit="34.1"/>
                    <measurement group_id="O2" value="17.0" lower_limit="10.4" upper_limit="25.5"/>
                    <measurement group_id="O3" value="32.4" lower_limit="23.7" upper_limit="42.1"/>
                    <measurement group_id="O4" value="37.9" lower_limit="28.5" upper_limit="48.0"/>
                    <measurement group_id="O5" value="42.9" lower_limit="33.2" upper_limit="52.9"/>
                    <measurement group_id="O6" value="43.1" lower_limit="33.4" upper_limit="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Total Migraine Freedom (TMF) at 2 Hours Post-Dose</title>
        <description>TMF at 2 hours post dose was defined as PF with no photophobia, phonophobia, nausea, or vomiting at 2 hours post-dose.</description>
        <time_frame>2 hours post-dose</time_frame>
        <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O2">
            <title>MK-1602 1 mg</title>
            <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O3">
            <title>MK-1602 10 mg</title>
            <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O4">
            <title>MK-1602 25 mg</title>
            <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O5">
            <title>MK-1602 50 mg</title>
            <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O6">
            <title>MK-1602 100 mg</title>
            <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Total Migraine Freedom (TMF) at 2 Hours Post-Dose</title>
          <description>TMF at 2 hours post dose was defined as PF with no photophobia, phonophobia, nausea, or vomiting at 2 hours post-dose.</description>
          <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="3.7" upper_limit="14.7"/>
                    <measurement group_id="O2" value="5.6" lower_limit="2.1" upper_limit="11.8"/>
                    <measurement group_id="O3" value="13.9" lower_limit="8.0" upper_limit="21.9"/>
                    <measurement group_id="O4" value="20.4" lower_limit="13.1" upper_limit="29.5"/>
                    <measurement group_id="O5" value="20.0" lower_limit="12.8" upper_limit="28.9"/>
                    <measurement group_id="O6" value="23.5" lower_limit="15.7" upper_limit="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting TMF at 2-24 Hours Post-Dose</title>
        <description>TMF at 2-24 hours post-dose was defined as SPF with no photophobia, phonophobia, nausea, or vomiting during the 2 to 24 hour period after dosing with study medication.</description>
        <time_frame>2-24 hours post-dose</time_frame>
        <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O2">
            <title>MK-1602 1 mg</title>
            <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O3">
            <title>MK-1602 10 mg</title>
            <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O4">
            <title>MK-1602 25 mg</title>
            <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O5">
            <title>MK-1602 50 mg</title>
            <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O6">
            <title>MK-1602 100 mg</title>
            <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting TMF at 2-24 Hours Post-Dose</title>
          <description>TMF at 2-24 hours post-dose was defined as SPF with no photophobia, phonophobia, nausea, or vomiting during the 2 to 24 hour period after dosing with study medication.</description>
          <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="106"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="2.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="4.7" lower_limit="1.5" upper_limit="10.6"/>
                    <measurement group_id="O3" value="9.3" lower_limit="4.5" upper_limit="16.4"/>
                    <measurement group_id="O4" value="12.6" lower_limit="6.9" upper_limit="20.6"/>
                    <measurement group_id="O5" value="14.2" lower_limit="8.1" upper_limit="22.3"/>
                    <measurement group_id="O6" value="20.6" lower_limit="13.2" upper_limit="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting TMF at 2-48 Hours Post-Dose</title>
        <description>TMF at 2-48 hours post-dose was defined as SPF with no photophobia, phonophobia, nausea, or vomiting during the 2 to 48 hour period after dosing with study medication.</description>
        <time_frame>2-48 hours post-dose</time_frame>
        <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O2">
            <title>MK-1602 1 mg</title>
            <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O3">
            <title>MK-1602 10 mg</title>
            <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O4">
            <title>MK-1602 25 mg</title>
            <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O5">
            <title>MK-1602 50 mg</title>
            <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
          <group group_id="O6">
            <title>MK-1602 100 mg</title>
            <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting TMF at 2-48 Hours Post-Dose</title>
          <description>TMF at 2-48 hours post-dose was defined as SPF with no photophobia, phonophobia, nausea, or vomiting during the 2 to 48 hour period after dosing with study medication.</description>
          <population>Participants from the Full Analysis Set, all participants who received treatment and had both a Baseline and at least one post-dose efficacy measurement, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="106"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="2.0" upper_limit="11.2"/>
                    <measurement group_id="O2" value="4.7" lower_limit="1.5" upper_limit="10.6"/>
                    <measurement group_id="O3" value="9.3" lower_limit="4.5" upper_limit="16.4"/>
                    <measurement group_id="O4" value="12.6" lower_limit="6.9" upper_limit="20.6"/>
                    <measurement group_id="O5" value="13.2" lower_limit="7.4" upper_limit="21.2"/>
                    <measurement group_id="O6" value="19.6" lower_limit="12.4" upper_limit="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All Subjects as Treated Population, all randomized participants who received at least 1 dose of study treatment, was used to determine the number of participants at risk for Serious Adverse Events (SAE) and Other Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
        <group group_id="E2">
          <title>MK-1602 1 mg</title>
          <description>MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
        <group group_id="E3">
          <title>MK-1602 10 mg</title>
          <description>MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
        <group group_id="E4">
          <title>MK-1602 25 mg</title>
          <description>MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
        <group group_id="E5">
          <title>MK-1602 50 mg</title>
          <description>MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
        <group group_id="E6">
          <title>MK-1602 100 mg</title>
          <description>MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Myoclonus</sub_title>
                <description>SAE: Myoclonus occurred 15 days post-dose.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

